Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML16: Intensive and Non-intensive Therapy for Older Patients with AML or High-risk MDS
NCT00454480Phase 3Completed
- Sponsor
- University of New South Wales
- Start
- Aug 2006
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin, clofarabine, azacitidine and arsenic trioxide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of New South Wales. Started Aug 2006; status: completed.
02
Drugs
gemtuzumab ozogamicinclofarabineazacitidinearsenic trioxide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00454480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454480.